In this article, we will discuss Olaparib (Patient Selection-2). So, let’s get started. Patient Selection for gBRCAm HER2-negative Metastatic Breast Cancer Select patients for the treatment of HER2-negative metastatic breast cancer with Lynparza based on the presence of deleterious or suspected deleterious gBRCA-mutation.
Tag: Olaparib
In this article, we will discuss Olaparib (Patient Selection-1). So, let’s get started. Patient Selection for gBRCAm Advanced Ovarian Cancer Select patients for the treatment of advanced ovarian cancer with Olaparib based on the presence of deleterious or suspected deleterious BRCA-mutations.
In this article, we will discuss Olaparib (Dosage-1). So, let’s get started. Olaparib is also available as a 50 mg capsule. DO NOT substitute Olaparib tablets (100 mg and 150 mg) with Olaparib capsules (50 mg) on a milligram-to-milligram basis due to differences in the dosing and bioavailability of each formulation.
In this article, we will discuss Olaparib (Usage-3). So, let’s get started. Germline BRCA-mutated HER2-negative Metastatic Breast Cancer Olaparib is indicated in patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have […]
In this article, we will discuss Olaparib (Usage-2). So, let’s get started. Advanced gBRCA-mutated Ovarian Cancer After 3 or More Lines of Chemotherapy Olaparib is indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. […]
In this article, we will discuss Olaparib (Usage-1). So, let’s get started. Usage Maintenance Treatment of Recurrent Ovarian Cancer Lynparza is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.